A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)
This is a study to evaluate the effectiveness of an investigational drug in patients with cancer of the lung.
Carcinoma, Non-Small-Cell Lung
DRUG: MK0457
Efficacy of MK0457 as a 5 day infusion as measured by radiological exams at baseline and after every other cycle of treatment. After 3 post-treatment radiological assessments, response will be measured after every third cycle., 5 Days
Safety and tolerability as measured by duration, intensity (grade) and time of onset of toxicity., 5 Days
This is a study to evaluate the effectiveness of an investigational drug in patients with cancer of the lung.